EORTC 22996-24002/TROG 01.01 - EPO Head & Neck

By w.paterson
14 August, 2021
0 Comments

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

Primary Sponsor

EORTC

Collaborating Groups

TROG Cancer Research

1 October, 2024

A plan for the future of cancer research

12 September 2024: TROG Cancer Research has outlined how

TOPGEAR trial results published in the New England Journal of Medicine

18 September, 2024

TOPGEAR trial findings published in NEJM

18 September 2024: We’re thrilled to announce the release

Join us to raise $20,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

TROG 99.06 – Bladder (Phase II)

Related Post

A plan for the future of cancer research

TOPGEAR trial findings published in NEJM

Join us to raise $20,000

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

TROG 99.06 – Bladder (Phase II)

Related Post

A plan for the future of cancer research

TOPGEAR trial findings published in NEJM

Join us to raise $20,000